As of 2024-12-15, the Fair Value of Hansa Biopharma AB (HNSA.ST) is -48.28 SEK. This value is based on the Peter Lynch's Fair Value formula. With the current market price of 29.38 SEK, the upside of Hansa Biopharma AB is -264.33%.
Note: valuation result may not be accurate due to the company's negative EPS.
Peter Lynch's formula is:
The earnings growth rate we use in the formula is the average growth rate of net income/earnings over the last 5 years. If the average growth rate is smaller than 5%, we set it to 5%. If it is larger than 25%, we set it to 25%. If the TTM EPS is negative, Peter Lynch Fair Value's result can be unreliable.
| Historical Earnings | ||||||
| 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 5Y Avg | |
| Net income | -360.01 | -420.85 | -548.28 | -611.13 | -831.72 | -554.40 |
| YoY growth | -45.18% | -16.90% | -30.28% | -11.46% | -36.09% | -27.98% |
| Market Cap (mil) | 1,992.26 |
| P/E | |
| Forward P/E |
| EPS | -9.66 |
| Avg earnings growth rate | -27.98% |
| TTM earnings | -654.78 |